About RCE
RCE (RCE.ai) is a medical technology company in Carlsbad, California. It works on early heart attack detection with Infrasensor, a non-invasive wearable that uses infrared. A transdermal approach and deep learning link optical signatures to cardiac conditions in real time. The platform has three parts. Infra-sensor is the device that measures cardiac conditions without a blood draw. Infra-mind is an AI and machine learning platform built to predict heart attacks. Infra-weave hosts, processes and analyzes the data. RCE aims the real-time assessment at emergency medicine physicians and cardiologists who see patients with chest pain.
RCE launched in 2018. Atandra Burman is founder and chief executive officer, and Jitto Titus, PhD, is chief scientific officer. The scientific advisory board includes Partho Sengupta, MD, Allan S. Jaffe, MD, Alan H. B. Wu, PhD, and Frank Peacock, MD. One study enrolled 840 people at 10 hospital locations in the United States. Participants wore the Infrasensor for three minutes while blood samples were collected for lab analysis. The technology is still in clinical studies. It is not yet FDA approved and is not for sale in the US. The company's address is 2292 Faraday Ave, #19, Carlsbad, CA 92008.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Oct 23, 2026 | $110,000of $3.0M target | 2 | $55,000 | EquityRule 506(b) | Form D ↗ |
| Dec 2, 2025 | Dec 17, 2025 | $25,000of $2.0M target | 3 | $8,333 | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Nov 20, 2023 | Dec 5, 2023amended Nov 20, 2025 | $2,137,000fully sold | 37 | $57,757 | Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗6 earlier filings |
| Jun 22, 2022 | Jun 23, 2022amended Dec 5, 2023 | $1,677,000of $2.0M target | 43 | $39,000 | Options, Securities on exerciseRule 506(b) | Form D/A ↗7 earlier filings |
| Jul 30, 2021 | Aug 4, 2021amended Jan 25, 2022 | $1,345,000of $2.0M target | 14 | $96,071 | OptionsRule 506(b) | Form D/A ↗4 earlier filings |
| Jan 11, 2019 | Oct 30, 2019amended Jun 14, 2021 | $610,000of $2.0M target | 23 | $26,522 | OptionsRule 506(b) | Form D/A ↗10 earlier filings |
| Total, six offerings | $5,904,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed RCE
RCE Technologies is a Carlsbad, California, company building a wrist-worn infrared sensor and AI software for early heart attack detection. It targets emergency physicians and cardiologists who assess patients with chest pain. The device is still in clinical studies and has no FDA approval. A study at 10 U.S. hospitals and a win at an American Heart Association competition mark its progress so far.
The problem it targets
A heart attack diagnosis requires a rise or fall in plasma troponin, according to a Nature Reviews Cardiology review that RCE highlights. RCE's aim is a bedside troponin reading with no blood draw. Dr. W. Frank Peacock, a Baylor College of Medicine professor of emergency medicine, offered his view of the technology. He said it could speed diagnosis for emergency physicians. He also said it could help EMTs pass critical patient data from the scene to the emergency room.
What the product does
RCE treats the device as more than a one-off test. Dr. Partho Sengupta stresses the value of continuous biomarkers and the change in values over time. He also points to uses beyond the emergency department. The company sees potential for its platform in emergency care and in remote monitoring.
Progress so far
Dr. Peacock highlighted the 840-person study at a biomarkers symposium in La Jolla on May 3, 2024. At ACC.24, RCE showed first-in-human continuous monitoring from its wrist wearable, with real-time biomarker trends. It won the Health Tech Competition at the American Heart Association's Scientific Sessions 2023. It was also selected for the Cedars-Sinai Accelerator program. Editors at European Heart Journal – Digital Health reviewed a published paper on the wrist-worn sensor. The device is not FDA approved, and the company hopes its clinical studies lead to approval.
We wrote this summary from public statements by RCE and its investors. It is not investment advice.
RCE in the News
Leadership Team
Executive officers and directors listed on RCE's Form D filed Oct 23, 2026.
Sources
- SECRCE Technologies, Inc. Form D/A, filed Mar 20, 2025
- SECRCE Technologies, Inc. Form D/A, filed Sep 30, 2024
- SECRCE Technologies, Inc. Form D/A, filed Jun 20, 2024
- SECRCE Technologies, Inc. Form D/A, filed Feb 28, 2024
- SECRCE Technologies, Inc. Form D/A, filed Jan 5, 2024
- SECRCE Technologies, Inc. Form D, filed Dec 5, 2023
- SECRCE Technologies, Inc. Form D/A, filed Sep 14, 2023
- SECRCE Technologies, Inc. Form D/A, filed Jan 6, 2023
- SECRCE Technologies, Inc. Form D/A, filed Dec 14, 2022
- SECRCE Technologies, Inc. Form D/A, filed Nov 22, 2022
- SECRCE Technologies, Inc. Form D/A, filed Nov 7, 2022
- SECRCE Technologies, Inc. Form D/A, filed Aug 31, 2022
- SECRCE Technologies, Inc. filing history
- CompanyRCE about page
- CompanyRCE team page
- CompanyRCE press release, May 7, 2024 (Biomarker Symposium)
- CompanyRCE release, November 13, 2023 (Health Tech Competition)